CDSCO rules out review or recall of 33 drugs approved between ... pharmabiz.com The drugs in question include everolimus by Novartis, colistimethate by Cipla, exemestane by Pharmacia, buclizine by UCB, pemetrexid by Eli Lilly, aliskiren by ... |
CDSCO rules out review or recall of 33 drugs approved between ... pharmabiz.com The drugs in question include everolimus by Novartis, colistimethate by Cipla, exemestane by Pharmacia, buclizine by UCB, pemetrexid by Eli Lilly, aliskiren by ... |